stockrow
Friday 6 November 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
49.92
1.36
+2.80%
Follow CRSP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1,343.49 | 1,113.61 | 393.06 | 212.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(50.95) | (41.96) | (63.04) | (59.67) | |
P/B ratio |
2.45 | 2.52 | 3.01 | 3.25 | |
Price to Tangible BV |
2.45 | 2.52 | 3.01 | 3.25 | |
EV/Sales |
845.25 | 661.18 | 260.28 | 145.64 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.60) | (6.78) | (9.43) | (9.79) | |
EV/FCF |
(8.58) | (6.76) | (9.39) | (9.73) | |
Quick Ratio |
13.25 | 17.92 | 17.79 | 16.12 | |
Current Ratio |
13.32 | 17.96 | 17.85 | 16.21 | |
Net Debt/EBITDA |
13.25 | 14.74 | 15.74 | 13.40 | |
Debt/Assets |
0.00% | 21.48% | 22.11% | 22.96% | |
Debt/Equity |
0.00 | 0.32 | 0.34 | 0.36 | |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.01 | |
Operating CF/Net income |
0.71 | 0.89 | 0.92 | 0.80 | |
Capex/Depreciation |
(0.09) | (0.12) | (0.15) | (0.10) | |
Research and Development Expense of Revenue |
9,667.36% | 4,703.29% | 683.87% | 659.59% | |
Selling, General and Administrative Expense of Revenue |
2,129.51% | 1,178.53% | 172.41% | 141.03% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2,092.13% | 1,119.62% | 170.08% | 141.77% | |
Graham Net Nets |
0.35 | 0.34 | 0.28 | 0.26 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.43%) | (13.08%) | (8.73%) | (8.57%) | |
Free Cash Flow Yield |
(7.34%) | (8.78%) | (7.05%) | (7.04%) | |
Revenue per Share |
0.01 | 0.02 | 0.11 | 0.13 | |
Operating CF per Share |
(1.03) | (1.13) | (0.87) | (0.93) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.03) | (1.14) | (0.87) | (0.93) | |
Cash per Share |
21.97 | 25.42 | 24.50 | 23.49 | |
Shareholders Equity per Share |
21.37 | 18.89 | 18.10 | 17.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.37 | 18.89 | 18.10 | 17.04 | |
Free Cash Flow |
(93.07) | (109.40) | (84.15) | (90.10) | |
Working Capital |
1,836.55 | 2,312.08 | 2,238.87 | 2,144.12 | |
Capital Expenditures |
(0.52) | (0.50) | (0.65) | (0.41) | |
Net Current Asset Value |
1,642.24 | 1,537.10 | 1,467.55 | 1,376.74 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.60 | 0.35 | 0.06 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
12.92 | 13.36 | 10.53 | 16.19 | |
Average Assets |
2,253.64 | 2,445.96 | 2,340.24 | 2,400.86 | |
Average Common Equity |
1,926.95 | 1,821.86 | 1,728.84 | 1,782.03 |
Columns are period end dates · fundamentals updated 6 Nov 2026